A Message From Our Chief Medical Office
The COVID-19 pandemic has forever changed the way we live and work. As an essential service provider, we are committed to be a responsible partner to our communities and continue to contribute towards the advancement of clinical research and drug development. At BioPharma, we have strived to take every precaution to keep our community safe. With that in mind, and in line with current public health guidelines, we will be making the following change to our protocols.
Effective February 15, 2022, all visitors to our Toronto, Canada facility including clinical trial volunteers, sponsors and vendors, will be required to show proof of vaccination status prior to entry. Specifically, volunteers will only be screened into a study if they can attest that they are fully vaccinated. An individual will be considered fully vaccinated if
- they have received the second dose of a two-dose COVID-19 vaccine series (e.g., Pfizer-BioNTech Comirnaty, Moderna Spikevax, AstraZeneca Vaxzevria)
- they have received one dose of a one-dose COVID-19 vaccine series (e.g., Janssen (Johnson & Johnson))
- 14 days have passed since the final dose.
We recognize that this change to our procedure will impact some volunteers who are currently in-study or have outstanding study returns, so we are working closely with our volunteer community to ensure any disruption to studies is minimized. As always, you can be assured that we will continue to provide you, our valued clients, with service excellence.
If you have any questions, please reach out to your usual BioPharma Services contact to discuss your concerns.
Yours in Health,
Dr. F. Abuzgaya – Chief Medical Officer & Principal Investigator
Best Practice Procedures
We have also been quick to respond and restructure our operations in the following months to mitigate any risks. As always, our research facilities adhere to best practice guidelines recommended by Health Canada and the US Food and Drug Administration.
Since the start of the pandemic, BioPharma has finalized and released multiple SOPs to govern our operating procedures under the new COVID-19 norm. Our operations in Toronto have been classified as an essential research service by our Government Member of Parliament and continues to operate under this distinction regardless of provincial lockdowns and/or restrictions. We continue to enforce our in-house COVID-19 procedures for all staff, subjects and guests to our facility which include (but not limited) to the following:
- Pre-screening questionnaire and thermal temperature scan
- Cleaning and disinfecting protocols
- Hand hygiene and access to sanitizing solutions
- Personal protective equipment (face shields, masks and gloves) including universal masking while on site
- Social and physical distancing protocols in all areas of our facilities
Safety – Our First Priority From Renzo DiCarlo
To date, both BioPharma’s sites in Toronto and St. Louis have not reported any community spread or outbreak of the COVID-19 virus. In fact, our Toronto site has been found by Canada’s largest local public health agency to have safety measures that are “above and beyond” government protocols.
The safety of our colleagues, volunteers, sponsors and community will always be our top priority.
A message from our CEO can be found by following this link; https://www.biopharmaservices.com/news/a-message-from-our-chief-executive-officer-renzo-dicarlo/
Renzo DiCarlo, CEO
If you’re a volunteer, concerned about taking part in a trial during the pandemic, please contact us so we can answer your questions. We are taking proactive measures to create a safe environment in all our clinics. Click here to see what we’ve done to prioritize your safety.
If you’re a sponsor with questions about trial execution, please contact us by completing the form below to review our protocols and safety record.
Schedule a Discovery
Complete the form to schedule a Discovery Call with one of our medical experts to learn how BioPharma Services can be your trusted clinical trial partner.